International Journal of Stem Cells

Korean Society for Stem Cell Research (한국줄기세포학회)
권호 표지
DOI QR코드

DOI QR Code

Guidelines for Manufacturing and Application of Organoids: Liver

  • Hye-Ran Moon (Stem Cell Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) ;
  • Seon Ju Mun (Stem Cell Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) ;
  • Tae Hun Kim (Department of Surgery, Hanyang University College of Medicine) ;
  • Hyemin Kim (Department of Predictive Toxicology, Korea Institute of Toxicology) ;
  • Dukjin Kang (Organoid Standards Initiative ) ;
  • Suran Kim (Organoid Standards Initiative) ;
  • Ji Hyun Shin (Department of Surgery, Hanyang University College of Medicine) ;
  • Dongho Choi (Department of Surgery, Hanyang University College of Medicine) ;
  • Sun-Ju Ahn (Organoid Standards Initiative ) ;
  • Myung Jin Son (Stem Cell Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB))
  • Received : 2024.04.08
  • Accepted : 2024.04.30
  • Published : 2024.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Recent amendments to regulatory frameworks have placed a greater emphasis on the utilization of in vitro testing platforms for preclinical drug evaluations and toxicity assessments. This requires advanced tissue models capable of accurately replicating liver functions for drug efficacy and toxicity predictions. Liver organoids, derived from human cell sources, offer promise as a reliable platform for drug evaluation. However, there is a lack of standardized quality evaluation methods, which hinders their regulatory acceptance. This paper proposes comprehensive quality standards tailored for liver organoids, addressing cell source validation, organoid generation, and functional assessment. These guidelines aim to enhance reproducibility and accuracy in toxicity testing, thereby accelerating the adoption of organoids as a reliable alternative or complementary tool to animal testing in drug development. The quality standards include criteria for size, cellular composition, gene expression, and functional assays, thus ensuring a robust hepatotoxicity testing platform.

Keywords

Acknowledgement

This work was supported by a grant (23212MFDS265 and 22213MFDS386) from the Ministry of Food and Drug Safety, Korea, in 2024.

References

  1. Han JJ. FDA Modernization Act 2.0 allows for alternatives to animal testing. Artif Organs 2023;47:449-450
  2. Berggren E, Worth AP. Towards a future regulatory framework for chemicals in the European Union - Chemicals 2.0. Regul Toxicol Pharmacol 2023;142:105431
  3. Olson H, Betton G, Robinson D, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000;32:56-67
  4. Baran SW, Brown PC, Baudy AR, et al. Perspectives on the evaluation and adoption of complex in vitro models in drug development: workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate). ALTEX 2022;39:297-314
  5. Moon HR, Surianarayanan N, Singh T, Han B. Microphysiological systems as reliable drug discovery and evaluation tools: evolution from innovation to maturity. Biomicrofluidics 2023;17:061504
  6. Zhao Z, Chen X, Dowbaj AM, et al. Organoids. Nat Rev Methods Primers 2022;2:94
  7. Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010;52:2065-2076
  8. Mun SJ, Ryu JS, Lee MO, et al. Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids. J Hepatol 2019;71:970-985
  9. Osonoi S, Takebe T. Organoid-guided precision hepatology for metabolic liver disease. J Hepatol 2024;80:805-821
  10. Zhang CJ, Meyer SR, O'Meara MJ, et al. A human liver organoid screening platform for DILI risk prediction. J Hepatol 2023;78:998-1006
  11. Brooks A, Liang X, Zhang Y, et al. Liver organoid as a 3D in vitro model for drug validation and toxicity assessment. Pharmacol Res 2021;169:105608
  12. Kim H, Im I, Jeon JS, et al. Development of human pluripotent stem cell-derived hepatic organoids as an alternative model for drug safety assessment. Biomaterials 2022;286:121575
  13. Takebe T, Sekine K, Enomura M, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 2013;499:481-484
  14. Shinozawa T, Kimura M, Cai Y, et al. High-fidelity druginduced liver injury screen using human pluripotent stem cell-derived organoids. Gastroenterology 2021;160:831-846.e10
  15. Marsee A, Roos FJM, Verstegen MMA, et al. Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids. Cell Stem Cell 2021;28:816-832
  16. Huch M, Gehart H, van Boxtel R, et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell 2015;160:299-312
  17. Kim HJ, Kim G, Chi KY, Kim JH. In vitro generation of luminal vasculature in liver organoids: from basic vascular biology to vascularized hepatic organoids. Int J Stem Cells 2023;16:1-15
  18. Guan Y, Enejder A, Wang M, et al. A human multi-lineage hepatic organoid model for liver fibrosis. Nat Commun 2021;12:6138
  19. Jensen KB, Little MH. Organoids are not organs: sources of variation and misinformation in organoid biology. Stem Cell Reports 2023;18:1255-1270
  20. Harrison SP, Siller R, Tanaka Y, et al. Scalable production of tissue-like vascularized liver organoids from human PSCs. Exp Mol Med 2023;55:2005-2024
  21. Salas-Silva S, Kim Y, Kim TH, et al. Human chemically-derived hepatic progenitors (hCdHs) as a source of liver organoid generation: application in regenerative medicine, disease modeling, and toxicology testing. Biomaterials 2023;303:122360
  22. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-872
  23. Kim JH, Mun SJ, Kim JH, Son MJ, Kim SY. Integrative analysis of single-cell RNA-seq and ATAC-seq reveals heterogeneity of induced pluripotent stem cell-derived hepatic organoids. iScience 2023;26:107675
  24. Ouchi R, Togo S, Kimura M, et al. Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids. Cell Metab 2019;30:374-384.e6
  25. Lee J, Gil D, Park H, et al. A multicellular liver organoid model for investigating hepatitis C virus infection and nonalcoholic fatty liver disease progression. Hepatology 2023 https://doi.org/10.1097/HEP.0000000000000683 [Epub ahead of print]
  26. Pek NMQ, Liu KJ, Nichane M, Ang LT. Controversies surrounding the origin of hepatocytes in adult livers and the in vitro generation or propagation of hepatocytes. Cell Mol Gastroenterol Hepatol 2021;11:273-290
  27. Sohlenius-Sternbeck AK. Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements. Toxicol In Vitro 2006;20:1582-1586
  28. Peng WC, Kraaier LJ, Kluiver TA. Hepatocyte organoids and cell transplantation: what the future holds. Exp Mol Med 2021;53:1512-1528
  29. Kim DS, Ryu JW, Son MY, et al. A liver-specific gene expression panel predicts the differentiation status of in vitro hepatocyte models. Hepatology 2017;66:1662-1674
  30. Lee MO, Lee SG, Jung CR, et al. Development of a quantitative prediction algorithm for target organ-specific similarity of human pluripotent stem cell-derived organoids and cells. Nat Commun 2021;12:4492
  31. Duran I, Pombo J, Sun B, et al. Detection of senescence using machine learning algorithms based on nuclear features. Nat Commun 2024;15:1041